Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Update on the Management of Takayasu Arteritis

Lara C. Pullen, PhD  |  February 4, 2020

In 2009, the European League Against Rheumatism (EULAR) published recommendations for the management of large vessel vasculitis. In the time since, researchers have published new data on the diagnosis, monitoring and treatment of this condition, and the new evidence has been incorporated into the 2018 recommendations.1 Ana F Agueda, MD, a rheumatology trainee at Centro Hospitalar do Baixo Vougar EPE, Portugal, and colleagues performed the extensive literature review used to inform the 2018 recommendations on one portion of the new guideline: the management of Takayasu arteritis. They published the results of their systematic literature review in the September 2019 issue of RMD Open.1

The literature review identified observational studies that provided low-level evidence to guide the monitoring and treatment of patients with Takayasu arteritis. The authors used a comprehensive research strategy and selected 287 articles for review. They note the heterogeneous nature of the articles made it impossible for them to perform a meta-analysis. Additionally, because Takayasu arteritis is a less common subtype of large vessel vasculitis, the recommendations are supported by less data than recommendations for more common forms. The researchers call for more, higher quality studies on the diagnosis, management and treatment of this rare disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Unlike the giant cell arteritis (GCA) form of large vessel vasculitis, which presents with a classical cranial pattern of symptoms, the presentation of Takayasu arteritis is heterogeneous and has no clear pattern. Patients with Takayasu arteritis not only have vascular symptoms, but may also present with systemic symptoms, such as fever, weight loss and malaise. The investigators found sex and age were both associated with some differences in disease manifestations. Men with Takayasu arteritis tended to have a greater risk of abdominal pain and ascending aortic aneurysm than women with Takayasu arteritis. Men also tended to have an increased frequency of involvement of abdominal aorta, as well as more complications. In the studies, men more often experienced the common complications of hypertension and aortic valve regurgitation than women.

Patients who were older than 40 at the time of symptom onset tended to have a more diffuse pattern of vascular lesions and a higher rate of complications. The presence of major complications, being older than 40, a progressive disease course and a weaker inflammatory response were all associated with a more unfavorable prognosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers found no evidence detailing the best disease-monitoring scheme. They note that because the consequences of disease progression in Takayasu arteritis may be severe, rapid diagnosis and treatment can reduce the likelihood of vascular damage. They recommend medical centers establish fast-track clinics, such as those used for GCA, to help manage the treatment of patients with Takayasu arteritis.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:large-vessel vasculitisTakayasu’s ArteritisVasculitis

Related Articles

    Fellow’s Forum Case Report: Takayasu’s Arteritis

    May 1, 2014

    How this rare form of large-vessel vasculitis affects different portions, branches of aorta and ways to diagnose, treat and manage the disease

    New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

    October 10, 2016

    LONDON—New therapies are emerging for the two main forms of large-vessel vasculitis, giant cell arteritis (GCA) and Takayasu’s arteritis—particularly biologic therapies. But for just about every available treatment gap, drawbacks or limited evidence remain, with the results needing to be borne out in larger trials, an expert said at the Annual Congress of the European…

    Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

    October 11, 2021

    Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.

    Alisusha; Trueffelpix / shutterstock.com

    3 New Vasculitis Guidelines Discussed

    May 13, 2021

    The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences